Systemic radioligand therapy with 177Lu-PSMA I&T in patients with metastatic castration-resistant prostate cancer

Conclusions Radioligand therapy with 177Lu-PSMA I&T appears to be safe and active in heavily preatreated mCRPC patients. Further prospective, randomized and multicentric evaluation under a phase-III protocol is encouraged.

Source: Journal of Nuclear Medicine - May 23, 2016 Category: Nuclear Medicine Authors: Eiber, M., Heck, M., Tauber, R., Rauscher, I., D`Alessandria, C., Maurer, T., Retz, M., Wester, H., Schwaiger, M. Tags: CMIIT Young Investigator Award Source Type: research